Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280540 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 648
- Enrollment target
NCT00280540 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 648 participants.
The verdict
NCT00280540, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 648 participants
- Enrollment target
Study Summary
This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg compared to a more conventional approach (therapy initiated with low-dose valsartan 80 mg).
Interventions
- DRUG Valsartan/Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 648 participants |
| Start Date | 2005-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280540
The ClinicalTrials.gov registry entry for NCT00280540 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 648 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valsartan/Hydrochlorothiazide is the first listed.
NCT00280540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00280540 about?
NCT00280540 is a clinical study titled "Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension". This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg compared to a more conventional approach (therapy initiated with low-dose valsartan 80 mg).
What is the current status of trial NCT00280540?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 648 participants. The study started on 2005-12.
What interventions are being tested in trial NCT00280540?
The interventions under investigation include: Valsartan/Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00280540?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.